Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 52 min ago
Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer

837 Targeting a CD36-dependent macrophage immunometabolic program enhances PARP inhibitor response in BRCA-associated TNBC

  • Julie Collins1
  • Anita Mehta2
  • Adam Nelson3
  • Claudine Isaacs4
  • Filipa Lynce5
  • Kenichi Shimada6
  • Xue Geng7
  • Candace Mainor8
  • Mei Wei9
  • Hongkun Wang7
  • Kiran Kurmi10
  • Carlos Wagner S Wanderley3
11 more authors
  • Daniel E Michaud11
  • Jennifer L Guerriero12
  • Jessica E Thaxton13
  • Alexander P Gottlieb14
  • Gabriella Antonellis15
  • Kelly F Zheng3
  • Madeline G Townsend3
  • Paula R Pohlmann16
  • Arielle L Keeke17
  • Geoffrey I Shapiro18
  • Marcia C Haigis19
19 affiliations
  1. 1AstraZeneca, Gaithersburg, MD, USA
  2. 23Division of Breast Surgery, Department of Surgery, Brigham and Women’s Hospital, Boston, MA, USA
  3. 3Brigham and Women’s Hospital, Boston, MA, USA
  4. 49Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA
  5. 53Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
  6. 62Harvard Medical School, Boston, MA, USA
  7. 75Georgetown University, Washington, DC, USA
  8. 86MedStar Georgetown University Hospital, Washington, DC, USA
  9. 98University of Utah, Salt Lake City, UT, USA
  10. 104Department of Cell Biology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA
  11. 11Department of Surgery, Harvard Medical School, Boston, MA, USA
  12. 12Ludwig Center for Cancer Research at Harvard, Harvard Medical School, Boston, MA, USA
  13. 13University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
  14. 14Harvard University/Brigham and Women’s Hospital, Boston, MA, USA
  15. 15Harvard Medical School, Boston, MA, USA
  16. 16The University of Texas MD Anderson Cancer Center, Houston, TX, USA
  17. 17Atrium Health, Charlotte, NC, USA
  18. 18Dana Farber Cancer Institute, Boston, MA, USA
  19. 19Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA
Open at sourcePDFDOICite

Related

  1. Serine protease inhibitor from Trichinella spiralis ameliorates diet-induced obesity and adipose tissue inflammation through TIM-3-dependent macrophage reprogramming
    Mingwei Tong, Ge Liu, Guidong Ren +6
    PLOS PathogensPeer-reviewedCC BY 4.0Full textImmunologyPhysiologyPLOS
  2. Urinary apoptosis inhibitor of macrophage reflects renal inflammation and tubular damage in ANCA-associated vasculitis
    Shunsuke Takahashi, Yoshinori Takei, Mari Okada +4
    Scientific ReportsPeer-reviewedCC BYFull textGeneral medicineDOAJ
  3. Taxifolin alleviates podocyte injury and macrophage chemotaxis associated with diabetic nephropathy by directly targeting RBP1 identified via multi-omics and machine learning
    Zi-Xuan Wang, Wen-Xuan Wang, Qiong-Dan Liang +1
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyPMCCrossrefEurope PMC
  4. Macrophage immunometabolic programming in pulmonary arterial hypertension: prioritizing TET2 and METTL3/m⁶A
    Hui Meng, Juan Liao, Li Peng +1
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textImmunologyGeneral medicineFrontiersDOAJCrossref
  5. Nanotherapeutic macrophage reprogramming through immunometabolic and microbial modulation for sepsis treatment.
    Xintong Lu, Wenhui Wang, Bingjie Zhang +11
    Signal transduction and targeted therapyPeer-reviewedCC BY-NC-NDFull textGeneral biologyGeneral medicineEurope PMCDOAJ

Cite

BibTeXRIS
BibTeX
@article{collins2026targeting,
  title = {{837 Targeting a CD36-dependent macrophage immunometabolic program enhances PARP inhibitor response in BRCA-associated TNBC}},
  author = {Julie Collins and Anita Mehta and Adam Nelson and Claudine Isaacs and Filipa Lynce and Kenichi Shimada and Xue Geng and Candace Mainor and Mei Wei and Hongkun Wang and Kiran Kurmi and Carlos Wagner S Wanderley and Daniel E Michaud and Jennifer L Guerriero and Jessica E Thaxton and Alexander P Gottlieb and Gabriella Antonellis and Kelly F Zheng and Madeline G Townsend and Paula R Pohlmann and Arielle L Keeke and Geoffrey I Shapiro and Marcia C Haigis},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.0837},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.0837},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - 837 Targeting a CD36-dependent macrophage immunometabolic program enhances PARP inhibitor response in BRCA-associated TNBC
AU  - Julie Collins
AU  - Anita Mehta
AU  - Adam Nelson
AU  - Claudine Isaacs
AU  - Filipa Lynce
AU  - Kenichi Shimada
AU  - Xue Geng
AU  - Candace Mainor
AU  - Mei Wei
AU  - Hongkun Wang
AU  - Kiran Kurmi
AU  - Carlos Wagner S Wanderley
AU  - Daniel E Michaud
AU  - Jennifer L Guerriero
AU  - Jessica E Thaxton
AU  - Alexander P Gottlieb
AU  - Gabriella Antonellis
AU  - Kelly F Zheng
AU  - Madeline G Townsend
AU  - Paula R Pohlmann
AU  - Arielle L Keeke
AU  - Geoffrey I Shapiro
AU  - Marcia C Haigis
PY  - 2026
DA  - 2026/11/06
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.0837
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.0837
SN  - 2051-1426
ER  -